DermTech announced Tuesday that it had raised $5.6 million in Series B financing.La Jolla-based
The firm, which is developing and commercializing assays for skin samples collected non-invasively using adhesive biopsy methods, said proceeds from the financing will be used to fund further development, complete commercial validation of assays and achieve necessary laboratory accreditation.
The company reported that it has conducted several clinical studies, including one in the British Journal of Dermatology, that have demonstrated the assay's ability to distinguish melanoma from non-melanoma.
“The acquisition of the Series B Financing will help the Company tremendously as we continue to validate our assay and drive toward commercialization on this important tool for clinicians,” said John Dobak, M.D., CEO and president in an announcement. “We appreciate that our key investors support our vision and have funded this Series B financing.”